Back to results
US 12,715,915 B2Granted
Gout flare prevention methods using IL-1β blockers
OwnerJeff R. Peterson, John K. Botsoninventors
Life of this patent
Estimating the term…
Abstract
The present invention discloses methods to prevent gout flares using IL-1β inhibitors. A method of treating gout patients using methotrexate, canakinumab, and pegloticase is described.
Claims27
A method of inhibiting gout flares in a patient receiving gout treatment, comprising prior to the occurrence of gout flares administering a gout flare-ameliorating amount of at least one IL-1β inhibitor, at least one immunomodulatory agent, and at least one uricase;
- wherein at least one dose of the IL-1β inhibitor is administered either alone or in combination with the immunomodulatory agent prior to or concurrent with administration of the uricase;
- and wherein the uricase is administered alone or in combination with the immunomodulatory agent;
- wherein the at least one IL-1β inhibitor is selected from the group consisting of canakinumab, anakinra, gevokizumab, and rilonacept;
- and wherein the immunomodulatory agent is selected from the group consisting of methotrexate, mycophenolate, azathioprine, leflunomide, pomalidomide, lenalidomide, sulfasalazine diphenhydramine, cetirizine, famotidine, montelukast, acetaminophen, methylprednisolone, folic acid, and prednisone.
1 more element
A treatment regimen for inhibiting gout flares in a patient in need thereof, comprising:
- a) administering an immunomodulatory agent;
- wherein the immunomodulatory agent is selected from the group consisting of methotrexate, mycophenolate, azathioprine, leflunomide, pomalidomide, lenalidomide, sulfasalazine diphenhydramine, cetirizine, famotidine, montelukast, acetaminophen, methylprednisolone, folic acid, and prednisone;
- b) administering at least one dose of an IL-1β inhibitor;
- wherein the at least one IL-1β inhibitor is selected from the group consisting of canakinumab, anakinra, gevokizumab, and rilonacept;
- and
- c) administering a uricase,
- wherein at least one dose of an IL-1β inhibitor is administered either alone or in combination with the immunomodulatory agent;
- and wherein the uricase is administered for a period of time to control gout;
- and wherein the IL-1β inhibitor is administered prior to or concurrent with the first administration of the uricase.
6 more elements
Dependencies are inferred from the claim text.